{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:40:08Z","timestamp":1792467608446,"version":"4.5.0"},"reference-count":57,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Exp Pathol"],"DOI":"10.62347\/lvqo4465","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T02:39:28Z","timestamp":1764297568000},"page":"553-562","source":"Crossref","is-referenced-by-count":0,"title":["Membranous nephropathy - an antigen-specific disease: a paradigm shift in the understanding of this disease"],"prefix":"10.62347","volume":"18","author":[{"given":"Meyyappa Devan","family":"Rajagopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, Sethi S, Tong A, Vivarelli M and Wetzels J. Membranous nephropathy. Nat Rev Dis Primers 2021; 7: 69.","journal-title":"Nat Rev Dis Primers"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jfma.2014.11.002","article-title":"Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment","volume":"114","author":"Lai","year":"2015","unstructured":"Lai WL, Yeh TH, Chen PM, Chan CK, Chiang WC, Chen YM, Wu KD and Tsai TJ. Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment. J Formos Med Assoc 2015; 114: 102-11.","journal-title":"J Formos Med Assoc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions","volume":"100","author":"Heymann","year":"1959","unstructured":"Heymann W, Hackel DB, Harwood S, Wilson SG and Hunter JL. Production of nephrotic syndrome in rats by Freund’s adjuvants and rat kidney suspensions. Proc Soc Exp Biol Med 1959; 100: 660-4.","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"LH Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB and Salant DJ. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","unstructured":"Sethi S, Beck LH Jr, Glassock RJ, Haas M, De Vriese AS, Caza TN, Hoxha E, Lambeau G, Tomas NM, Madden B, Debiec H, D’Agati VD, Alexander MP, Amer H, Appel GB, Barbour SJ, Caravaca-Fontan F, Cattran DC, Casal Moura M, D’Avila DO, Eick RG, Garovic VD, Greene EL, Herrera Hernandez LP, Jennette JC, Lieske JC, Markowitz GS, Nath KA, Nasr SH, Nast CC, Pani A, Praga M, Remuzzi G, Rennke HG, Ruggenenti P, Roccatello D, Soler MJ, Specks U, Stahl RAK, Singh RD, Theis JD, Velosa JA, Wetzels JFM, Winearls CG, Yandian F, Zand L, Ronco P and Fervenza FC. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int 2023; 104: 1092-1102.","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"611317","DOI":"10.3389\/fmed.2020.611317","article-title":"A narrative review","volume":"7","author":"Moroni","year":"2020","unstructured":"Moroni G and Ponticelli C. Secondary membranous nephropathy. A narrative review. Front Med (Lausanne) 2020; 7: 611317.","journal-title":"Front Med (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","article-title":"The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border","volume":"79","author":"Kerjaschki","year":"1982","unstructured":"Kerjaschki D and Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 1982; 79: 5557-61.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1399-0039.1989.tb01741.x","article-title":"A DQA1 allele is strongly associated with idiopathic membranous nephropathy","volume":"34","author":"RW","year":"1989","unstructured":"Vaughan RW, Demaine AG and Welsh KI. A DQA1 allele is strongly associated with idiopathic membranous nephropathy. Tissue Antigens 1989; 34: 261-9.","journal-title":"Tissue Antigens"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Prabakaran T, Nielsen R, Larsen JV, Sørensen SS, Feldt-Rasmussen U, Saleem MA, Petersen CM, Verroust PJ and Christensen EI. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. PLoS One 2011; 6: e25065.","DOI":"10.1371\/journal.pone.0025065"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"FC","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P and Cattran DC; MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381: 36-46.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S0140-6736(04)17142-0","article-title":"Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies","volume":"364","author":"Debiec","year":"2004","unstructured":"Debiec H, Nauta J, Coulet F, van der Burg M, Guigonis V, Schurmans T, de Heer E, Soubrier F, Janssen F and Ronco P. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364: 1252-9.","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy","volume":"8","author":"Rojas-Rivera JE","year":"2023","unstructured":"Rojas-Rivera JE, Ortiz A and Fervenza FC. Novel treatments paradigms: membranous nephropathy. Kidney Int Rep 2023; 8: 419-431.","journal-title":"Kidney Int Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"8963","DOI":"10.1074\/jbc.270.15.8963","article-title":"Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization","volume":"270","author":"Ancian","year":"1995","unstructured":"Ancian P, Lambeau G, Mattéi MG and Lazdunski M. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem 1995; 270: 8963-70.","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski B","year":"2016","unstructured":"Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VL and Lambeau G. Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol 2016; 27: 1517-33.","journal-title":"J Am Soc Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1681\/ASN.2019030273","article-title":"Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy","volume":"31","author":"Reinhard","year":"2020","unstructured":"Reinhard L, Zahner G, Menzel S, Koch-Nolte F, Stahl RAK and Hoxha E. Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy. J Am Soc Nephrol 2020; 31: 197-207.","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","unstructured":"Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M and Brenchley PE. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013; 83: 940-8.","journal-title":"Kidney Int"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Ma X, Wang R, Wei L, Liu P, Jing L, Wang J, Dong W, Tian X and Fu R. A comparison of chemiluminescent immunoassay and enzyme-linked immunosorbent assay for detecting phospholipase A2 receptor antibody in primary membranous nephropathy. Pract Lab Med 2024; 39: e00385.","DOI":"10.1016\/j.plabm.2024.e00385"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/nep.12478","article-title":"Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy","volume":"20","author":"Kumar","year":"2015","unstructured":"Kumar V, Ramachandran R, Kumar A, Nada R, Suri D, Gupta A, Kohli HS, Gupta KL and Jha V. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy. Nephrology (Carlton) 2015; 20: 572-5.","journal-title":"Nephrology (Carlton)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","unstructured":"Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RAK and Lambeau G. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371: 2277-2287.","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1056\/NEJMc1500130","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"372","author":"G&#xF6","year":"2015","unstructured":"Gödel M, Grahammer F and Huber TB. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2015; 372: 1073.","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1681\/ASN.2018090941","article-title":"Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes","volume":"30","author":"Herwig","year":"2019","unstructured":"Herwig J, Skuza S, Sachs W, Sachs M, Failla AV, Rune G, Meyer TN, Fester L and Meyer-Schwesinger C. Thrombospondin type 1 domain-containing 7A localizes to the slit diaphragm and stabilizes membrane dynamics of fully differentiated podocytes. J Am Soc Nephrol 2019; 30: 824-839.","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","unstructured":"Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, Wenzel U, Janneck M, Steinmetz OM, Panzer U, Harendza S and Stahl RA. A mechanism for cancer-associated membranous nephropathy. N Engl J Med 2016; 374: 1995-6.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","unstructured":"Hoxha E, Beck LH Jr, Wiech T, Tomas NM, Probst C, Mindorf S, Meyer-Schwesinger C, Zahner G, Stahl PR, Schöpper R, Panzer U, Harendza S, Helmchen U, Salant DJ and Stahl RA. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol 2017; 28: 520-531.","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New ‘Antigens’ in Membranous Nephropathy","volume":"32","author":"Sethi","year":"2021","unstructured":"Sethi S. New ‘Antigens’ in Membranous Nephropathy. J Am Soc Nephrol 2021; 32: 268-278.","journal-title":"J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/Exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","unstructured":"Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, Hummel AM, Specks U, Fervenza FC and Ronco P. Exostosin 1\/Exostosin 2-associated membranous nephropathy. J Am Soc Nephrol 2019; 30: 1123-1136.","journal-title":"J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","unstructured":"Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross L, Ravindran A, Buob D, Jadoul M, Fervenza FC and Ronco P. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020; 97: 163-174.","journal-title":"Kidney Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","unstructured":"Al-Rabadi LF, Caza T, Trivin-Avillach C, Rodan AR, Andeen N, Hayashi N, Williams B, Revelo MP, Clayton F, Abraham J, Lin E, Liou W, Zou CJ, Ramkumar N, Cummins T, Wilkey DW, Kawalit I, Herzog C, Storey A, Edmondson R, Sjoberg R, Yang T, Chien J, Merchant M, Arthur J, Klein J, Larsen C and Beck LH Jr. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol 2021; 32: 1666-1681.","journal-title":"J Am Soc Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","unstructured":"Sethi S, Debiec H, Madden B, Vivarelli M, Charlesworth MC, Ravindran A, Gross L, Ulinski T, Buob D, Tran CL, Emma F, Diomedi-Camassei F, Fervenza FC and Ronco P. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int 2020; 98: 1253-1264.","journal-title":"Kidney Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","unstructured":"Sethi S, Madden B, Debiec H, Morelle J, Charlesworth MC, Gross L, Negron V, Buob D, Chaudhry S, Jadoul M, Fervenza FC and Ronco P. Protocadherin 7-associated membranous nephropathy. J Am Soc Nephrol 2021; 32: 1249-1261.","journal-title":"J Am Soc Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","unstructured":"Sethi S, Madden B, Casal Moura M, Nasr SH, Klomjit N, Gross L, Negron V, Charlesworth MC, Alexander MP, Leung N, Specks U, Fervenza FC and Haas M. Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1. J Am Soc Nephrol 2022; 33: 1033-1044.","journal-title":"J Am Soc Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1681\/ASN.2022050608","article-title":"Netrin G1 is a novel target antigen in primary membranous nephropathy","volume":"33","author":"Reinhard","year":"2022","unstructured":"Reinhard L, Machalitza M, Wiech T, Gröne HJ, Lassé M, Rinschen MM, Ferru N, Bräsen JH, Drömann F, Rob PM, Sethi S, Hoxha E and Stahl RAK. Netrin G1 is a novel target antigen in primary membranous nephropathy. J Am Soc Nephrol 2022; 33: 1823-1831.","journal-title":"J Am Soc Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.kint.2021.08.014","article-title":"Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy","volume":"100","author":"Quintrec M","year":"2021","unstructured":"Le Quintrec M, Teisseyre M, Bec N, Delmont E, Szwarc I, Perrochia H, Machet MC, Chauvin A, Mavroudakis N, Taieb G, Lanfranco L, Rigothier C, José B, Concetta C, Geneste C, Pernin V, Larroque C, Devaux J and Beyze A. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int 2021; 100: 1240-1249.","journal-title":"Kidney Int"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.kint.2020.09.016","article-title":"Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis","volume":"100","author":"Caza","year":"2021","unstructured":"Caza TN, Hassen SI, Kuperman M, Sharma SG, Dvanajscak Z, Arthur J, Edmondson R, Storey A, Herzog C, Kenan DJ and Larsen CP. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int 2021; 100: 171-181.","journal-title":"Kidney Int"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.34067\/KID.0001492021","article-title":"Transforming Growth Factor Beta Receptor 3 (TGFBR3)-associated membranous nephropathy","volume":"2","author":"Caza","year":"2021","unstructured":"Caza TN, Hassen SI, Kenan DJ, Storey A, Arthur JM, Herzog C, Edmondson RD, Bourne TD, Beck LH Jr and Larsen CP. Transforming Growth Factor Beta Receptor 3 (TGFBR3)-associated membranous nephropathy. Kidney360 2021; 2: 1275-1286.","journal-title":"Kidney360"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1681\/ASN.0000000000000061","article-title":"Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor","volume":"34","author":"Sethi","year":"2023","unstructured":"Sethi S, Madden B, Casal Moura M, Singh RD, Nasr SH, Hou J, Sharma A, Nath KA, Specks U, Fervenza FC and Haas M. Membranous nephropathy in syphilis is associated with neuron-derived neurotrophic factor. J Am Soc Nephrol 2023; 34: 374-384.","journal-title":"J Am Soc Nephrol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.kint.2023.04.006","article-title":"Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use","volume":"104","author":"Sethi","year":"2023","unstructured":"Sethi S, Casal Moura M, Madden B, Debiec H, Nasr SH, Larsen CP, Gross L, Negron V, Singh RD, Nath KA, Storey AJ, Specks U, Fervenza FC, Ronco P and Caza TN. Proprotein convertase subtilisin\/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. Kidney Int 2023; 104: 343-352.","journal-title":"Kidney Int"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.kint.2023.01.001","article-title":"Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry","volume":"103","author":"Caza","year":"2023","unstructured":"Caza TN, Storey AJ, Hassen SI, Herzog C, Edmondson RD, Arthur JM, Kenan DJ and Larsen CP. Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int 2023; 103: 593-606.","journal-title":"Kidney Int"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.ekir.2024.02.1401","article-title":"Characteristics and outcomes of NELL1 membranous nephropathy in lipoic acid users and nonusers","volume":"9","author":"Avasare","year":"2024","unstructured":"Avasare RS, Clark S, Spain RI, Wusirika R, Rope R, Gurley S, Stanaway M, Sekulic M, Santoriello D, Bomback AS, Canetta P, Iyer SJ, Kung V, Charu V, Troxell ML, Kudose S and Andeen NK. Characteristics and outcomes of NELL1 membranous nephropathy in lipoic acid users and nonusers. Kidney Int Rep 2024; 9: 1379-1386.","journal-title":"Kidney Int Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.kint.2024.03.025","article-title":"NELL-1-associated membranous nephropathy linked to skin fairness cream use: insights from an Indian case series","volume":"105","author":"Narayanan","year":"2024","unstructured":"Narayanan R, Sivadas S and Kurien AA. NELL-1-associated membranous nephropathy linked to skin fairness cream use: insights from an Indian case series. Kidney Int 2024; 105: 1316-1319.","journal-title":"Kidney Int"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.kint.2020.06.014","article-title":"The clinicopathologic spectrum of segmental membranous glomerulopathy","volume":"99","author":"Kudose","year":"2021","unstructured":"Kudose S, Santoriello D, Debiec H, Canetta PA, Bomback AS, Stokes MB, Batal I, Ronco P, D’Agati VD and Markowitz GS. The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney Int 2021; 99: 247-255.","journal-title":"Kidney Int"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1681\/ASN.2020081181","article-title":"In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes","volume":"32","author":"Ravindran","year":"2021","unstructured":"Ravindran A, Casal Moura M, Fervenza FC, Nasr SH, Alexander MP, Fidler ME, Herrera Hernandez LP, Zhang P, Grande JP, Cornell LD, Gross LA, Negron V, Jenson GE, Madden BJ, Charlesworth MC and Sethi S. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes. J Am Soc Nephrol 2021; 32: 695-706.","journal-title":"J Am Soc Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.ekir.2021.04.025","article-title":"The exostosin immunohistochemical status differentiates lupus membranous nephropathy subsets with different outcomes","volume":"6","author":"Sa&#xEF","year":"2021","unstructured":"Saïdi M, Brochériou I, Estève E, Tuffet S, Amoura Z, Miyara M, Belenfant X, Ulinski T, Rouvier P, Debiec H, Ronco P and Buob D. The exostosin immunohistochemical status differentiates lupus membranous nephropathy subsets with different outcomes. Kidney Int Rep 2021; 6: 1977-1980.","journal-title":"Kidney Int Rep"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/sj.ki.5000313","article-title":"Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival","volume":"69","author":"Guan","year":"2006","unstructured":"Guan F, Villegas G, Teichman J, Mundel P and Tufro A. Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival. Kidney Int 2006; 69: 1564-9.","journal-title":"Kidney Int"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/sj.ki.5002726","article-title":"Semaphorin3a disrupts podocyte foot processes causing acute proteinuria","volume":"73","author":"Tapia","year":"2008","unstructured":"Tapia R, Guan F, Gershin I, Teichman J, Villegas G and Tufro A. Semaphorin3a disrupts podocyte foot processes causing acute proteinuria. Kidney Int 2008; 73: 733-40.","journal-title":"Kidney Int"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1101\/gad.1486806","article-title":"Cadherins in development: cell adhesion, sorting, and tissue morphogenesis","volume":"20","author":"Halbleib","year":"2006","unstructured":"Halbleib JM and Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006; 20: 3199-214.","journal-title":"Genes Dev"},{"key":"ref45","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 2021; 100: S1-S276."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"HJL","year":"2020","unstructured":"Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM and Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-46.","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C and Haynes R. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117-27.","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","unstructured":"Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F and Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704.","journal-title":"J Am Soc Nephrol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","unstructured":"Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-4.","journal-title":"Kidney Int"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K and Sakhuja V. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007; 18: 1899-904.","journal-title":"J Am Soc Nephrol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","unstructured":"Praga M, Barrio V, Juárez GF and Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007; 71: 924-30.","journal-title":"Kidney Int"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","unstructured":"Ramachandran R, Hn HK, Kumar V, Nada R, Yadav AK, Goyal A, Kumar V, Rathi M, Jha V, Gupta KL, Sakhuja V and Kohli HS. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton) 2016; 21: 139-46.","journal-title":"Nephrology (Carlton)"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"FC","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P and Cattran DC; MENTOR Investigators. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381: 36-46.","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, Mani LY, Santostefano M, Feriozzi S, Quaglia M, Boscutti G, Ferrantelli A, Marcantoni C, Passerini P, Magistroni R, Alberici F, Ghiggeri GM, Ponticelli C and Ravani P; RI-CYCLO Investigators. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol 2021; 32: 972-82.","journal-title":"J Am Soc Nephrol"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Podestà MA, Trillini M, Portalupi V, Gennarini A, Tomatis F, Villa A, Perna A, Rubis N, Remuzzi G and Ruggenenti P. Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series. Am J Kidney Dis 2024; 83: 340-349, e1.","DOI":"10.1053\/j.ajkd.2023.08.010"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","unstructured":"Sethi S, Kumar S, Lim K and Jordan SC. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep 2020; 5: 1515-8.","journal-title":"Kidney Int Rep"}],"container-title":["International Journal of Clinical and Experimental Pathology"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ijcep\/18\/11\/ijcep0163240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:14:33Z","timestamp":1792466073000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ijcep\/18\/11\/ijcep0163240.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/lvqo4465","relation":{},"ISSN":["1936-2625"],"issn-type":[{"value":"1936-2625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}